Abstract:ObjectiveTo investigate the value of combined measurement of alpha-fetoprotein (AFP) and AFP-L3% in the diagnosis of hepatocellular carcinoma (HCC). MethodsA retrospective analysis was performed for serological parameters and clinical data of 1208 patients with chronic hepatitis, 1967 patients with liver cirrhosis, and 1569 patients with primary HCC who attended The Fifth Medical Center of Chinese PLA General Hospital from January 2010 to December 2017. The distribution of serum AFP and AFP-L3% was analyzed, and AFP alone, AFP-L3% alone, and AFP combined with AFP-L3% were compared in terms of sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). The correlation of AFP with AFP-L3 level and AFP-L3% was also analyzed. A one-way analysis of variance or the Kruskal-Wallis H test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. The Spearman rank correlation test was used for correlation analysis of continuous data, the Delong test was used for comparison of AUC, and logistic regression was used to establish the model of AFP combined with AFP-L3% for the diagnosis of HCC. ResultsThe HCC group had significantly higher serum levels of AFP and AFP-L3 than the liver cirrhosis group and the chronic hepatitis group (H=1107.3 and 1076.9, both P＜0.01). The HCC group had a significantly higher positive rate of AFP-L3% than the liver cirrhosis group and the chronic hepatitis group (30.9% vs 3.0%/2.8%, P＜0.01). The HCC group had a significantly higher level of AFP-L3 than the liver cirrhosis group and the chronic hepatitis group （3.3(0-13.4)% vs 0/0, H=1034.1, P＜001）. The correlation analysis showed that serum AFP was significantly correlated with AFP-L3 level (r=0.91, P＜0.01), and there was no correlation between AFP-L3% and AFP (r=0.04, P＞0.05). With specificity remaining the same, AFP combined with AFP-L3% had a significantly higher sensitivity in the diagnosis of HCC than AFP alone (26.6% vs 18.4%, P＜0.01) or AFP-L3% alone (36.6% vs 30.9%, P＜0.01). The subgroup analysis showed that for the samples with AFP ≥10 μg/L, AFP combined with AFP-L3% had a significantly higher AUC in the diagnosis of HCC than AFP alone (0.745 vs 0.701, P＜0.01); for the tumor with a diameter of ＞2 cm or hepatitis B-related liver cancer, AFP combined with AFP-L3% had a significantly higher sensitivity than AFP alone (27.6% vs 180%/27.7% vs 19.1%, both P＜0.01) or AFP-L3% alone (37.0% vs 30.3%/36.9% vs 31.8%, both P＜0.01). For the group with a tumor diameter of ≤2 cm and the group without hepatitis B-related liver cancer, there was no significant difference in sensitivity between AFP combined with AFP-L3% and AFP or AFP-L3% alone in the diagnosis of HCC (all P＞0.05). ConclusionAFP combined with AFP-L3% can significantly improve the sensitivity of HCC diagnosis and has a good clinical value in the diagnosis of hepatitis B-related liver cancer and liver cancer with a tumor diameter of ＞2 cm.

Reply to ‘Are the 5-hydroxymethylcytosine-based wd-scores really superior over α-fetoprotein for the early diagnosis of hepatocellular carcinoma?’

Comparison Between ACR CEUS LI-RADS and WFUMB-EFSUMB for Diagnosing Hepatocellular Carcinoma in High-Risk Patients

5-Hydroxymethylcytosines from Circulating Cell-free DNA As Diagnostic and Prognostic Markers for Hepatocellular Carcinoma

Genome-wide Plasma Cell-Free DNA Methylation Profiling to Identify High-Performing Biomarkers for Early Detection of Hepatocellular Carcinoma.

Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV‐related hepatocellular carcinoma

Genome-wide Mapping of 5-Hydroxymethylcytosines in Circulating Cell-Free DNA As a Non-Invasive Approach for Early Detection of Hepatocellular Carcinoma

Diagnostic Value of 5 Serum Biomarkers for Hepatocellular Carcinoma with Different Epidemiological Backgrounds: A Large-Scale, Retrospective Study

Abstract 782: the Genetic and Epigenetic Abnormalities of Plasma Cfdna As Liquid Biopsy Biomarkers to Diagnose Hepatocellular Carcinoma

Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study

Development and validation of a non-invasive cfDNA targeted sequencing assay for early-stage hepatocellular carcinoma detection using cfDNA methylation and fragmentomics.

Combined detection of circulating tumor cells, α-fetoprotein heterogene-3 and α-fetoprotein in the early diagnosis of HCC for the prediction of efficacy, prognosis, recurrence after microwave ablation

A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values

Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis

Combined Detection Of Circulating Tumor Cells, Alpha-Fetoprotein Heterogene-3 And Alpha-Fetoprotein In The Early Diagnosis Of Hcc For The Prediction Of Efficacy, Prognosis, Recurrence After Microwave Ablation

Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA

Direct Comparison of Five Serum Biomarkers in Early Diagnosis of Hepatocellular Carcinoma.

Value of combined measurement of alpha-fetoprotein and alpha-fetoprotein L3％in the diagnosis of hepatocellular carcinoma

Genome-Scale Profiling of Circulating Cell-Free DNA Signatures for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis

Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma

Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma